{"id":28034,"date":"2018-02-12T09:28:56","date_gmt":"2018-02-12T09:28:56","guid":{"rendered":"http:\/\/dominiclevent.com\/blog\/?p=28034"},"modified":"2019-04-17T17:14:53","modified_gmt":"2019-04-17T17:14:53","slug":"pharma-companies-prominent-in-list-of-top-defendants-in-us-patent-litigation-during-2017","status":"publish","type":"post","link":"https:\/\/dominiclevent.com\/blog\/pharma-companies-prominent-in-list-of-top-defendants-in-us-patent-litigation-during-2017\/","title":{"rendered":"Pharma companies prominent in list of top defendants in US patent litigation during 2017"},"content":{"rendered":"


\n<\/p>\n

\n

Teva was the most targeted company in US patent lawsuits last year taking the top spot from Samsung as pharmaceutical companies featured heavily in the leading defendants.<\/p>\n

The numbers come courtesy of Lex Machina\u2019s annual review<\/a> of patent litigation, which is the data analytics platform\u2019s deep dive into the headline numbers for 2017. While the ranking of most targeted companies\u00a0includes a typical blend of tech giants\u00a0such as\u00a0Apple, LG, Amazon, ZTE, Microsoft and Huawei, there was a significant jump in the number of pharma companies on the list – nine made the ranking, up from four last year.<\/p>\n

As well as Teva other drug companies that featured included Mylan, Sandoz, Apotex, Amneal and Lupin. Lex Machina\u2019s report also revealed a marked increase in ANDA litigation in 2017, with\u00a0the number of cases\u00a0rising\u00a0from 318 in 2016 to 411 last year. That placed the volume of new suits closer to the recent highs in 2015 and 2014 when 469 and 434 new ANDA cases were filed respectively. The top plaintiffs included a large number of NPEs\u00a0 but also several brand-name pharma giants such as Pfizer and Bristol-Myers Squibb.<\/p>\n

You can see the top patent litigation defendants for 2017 in the table below:\u00a0<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
1<\/td>\n

<\/p>\n

Teva<\/td>\n

<\/p>\n

49 cases<\/td>\n


\n\t\t<\/tr>\n

2<\/td>\n

<\/p>\n

Apple<\/td>\n

<\/p>\n

42 cases<\/td>\n


\n\t\t<\/tr>\n

3<\/td>\n

<\/p>\n

Samsung Electronics America<\/td>\n

<\/p>\n

37 cases<\/td>\n


\n\t\t<\/tr>\n

4<\/td>\n

<\/p>\n

LG Electronics<\/td>\n

<\/p>\n

30 cases<\/td>\n


\n\t\t<\/tr>\n

5<\/td>\n

<\/p>\n

Mylan Pharmaceuticals<\/td>\n

<\/p>\n

28 cases<\/td>\n


\n\t\t<\/tr>\n

6=<\/td>\n

<\/p>\n

Amazon.com<\/td>\n

<\/p>\n

25 cases<\/td>\n


\n\t\t<\/tr>\n

6=<\/td>\n

<\/p>\n

ZTE<\/td>\n

<\/p>\n

25 cases<\/td>\n


\n\t\t<\/tr>\n

8<\/td>\n

<\/p>\n

Aurobindo Pharma USA<\/td>\n

<\/p>\n

24 cases<\/td>\n


\n\t\t<\/tr>\n

9<\/td>\n

<\/p>\n

Huawei Device USA\u00a0<\/td>\n

<\/p>\n

23 cases<\/td>\n


\n\t\t<\/tr>\n

10<\/td>\n

<\/p>\n

Sandoz<\/td>\n

<\/p>\n

22 cases<\/td>\n


\n\t\t<\/tr>\n

11<\/td>\n

<\/p>\n

Microsoft\u00a0<\/td>\n

<\/p>\n

21 cases<\/td>\n


\n\t\t<\/tr>\n

12=<\/td>\n

<\/p>\n

Apotex<\/td>\n

<\/p>\n

19 cases<\/td>\n


\n\t\t<\/tr>\n

12=<\/td>\n

<\/p>\n

HTC<\/td>\n

<\/p>\n

19 cases<\/td>\n


\n\t\t<\/tr>\n

14=<\/td>\n

<\/p>\n

Amneal Pharmaceuticals<\/td>\n

<\/p>\n

18 cases<\/td>\n


\n\t\t<\/tr>\n

14=<\/td>\n

<\/p>\n

Lupin<\/td>\n

<\/p>\n

18 cases<\/td>\n


\n\t\t<\/tr>\n

14=<\/td>\n

<\/p>\n

Par Pharmaceutical<\/td>\n

<\/p>\n

18 cases<\/td>\n


\n\t\t<\/tr>\n

14=<\/td>\n

<\/p>\n

Zydus Pharmaceuticals\u00a0<\/td>\n

<\/p>\n

18 cases<\/td>\n


\n\t\t<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

Source: Lex Machina<\/em><\/p>\n

Many of the headline numbers for patent litigation in 2017 have already been reported. Last week, this blog did a thorough analysis<\/a> of what was another down year in the US. Lex Machina\u2019s dive goes into even greater detail and includes a look at the profound impact of the Supreme Court\u2019s decision in TC Heartland<\/a><\/em>. This\u00a0has seen a huge chunk of cases that might have previously been filed in the Eastern District of Texas move to other districts such as Delaware. \u00a0\u00a0<\/p>\n

As in previous year\u2019s this latest report also\u00a0focuses on\u00a0litigation volume across the last 10 years on a like-for-like basis in a way that accounts for the changes to the joinder rules introduced by the America Invents Act, which forced patent owners to file more patent suits separately. Using a measure which it calls defendant-case pairs, Lex Machina\u2019s analysis shows that for the last couple of years litigation in the US has been commensurate with levels last seen in 2008 and 2009.<\/p>\n

Among other highlights, the report also revealed an increase in the proportion of cases resulting in a claimant win; this\u00a0ticked up to 6.2% from 5.5% in 2016. Defendant wins fell from 4% to 3.4%. Total damages for the year meanwhile dropped to $1.15 billion (from 140 cases), a substantial fall from just over $3.5 billion in 2016 (from 151 cases).<\/p>\n

New subscriber offering coming in March<\/strong><\/p>\n

Big changes are on the way for the<\/strong>\u00a0IAM<\/em><\/strong>\u00a0platform: from March we will be providing subscribers with even more detailed analysis of and intelligence about developments in the global IP market, as well as giving them an exclusive first look at the\u00a0<\/strong>IAM Patent 1000<\/em>\u00a02018 rankings. While some content will remain free to view, non-subscribers will lose automatic access to the intelligence, analysis and data that we publish daily, and will not be able to view much of the new material that we will be offering to subscribers. Further details are <\/strong>available here<\/a>.\u00a0<\/strong><\/p>\n<\/p><\/div>\n


\n
Source link <\/a>
\n\"\"<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Teva was the most targeted company in US patent lawsuits last year taking the top spot from Samsung as pharmaceutical companies featured heavily in the leading defendants. The numbers come courtesy of Lex Machina\u2019s annual review of patent litigation, which is the data analytics platform\u2019s deep dive into the headline numbers for 2017. While the … <\/p>\n

Continue reading “Pharma companies prominent in list of top defendants in US patent litigation during 2017”<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-28034","post","type-post","status-publish","format-standard","hentry","entry"],"yoast_head":"\nPharma companies prominent in list of top defendants in US patent litigation during 2017 - Dominic Levent Solicitors Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dominiclevent.com\/blog\/pharma-companies-prominent-in-list-of-top-defendants-in-us-patent-litigation-during-2017\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma companies prominent in list of top defendants in US patent litigation during 2017 - Dominic Levent Solicitors Blog\" \/>\n<meta property=\"og:description\" content=\"Teva was the most targeted company in US patent lawsuits last year taking the top spot from Samsung as pharmaceutical companies featured heavily in the leading defendants. The numbers come courtesy of Lex Machina\u2019s annual review of patent litigation, which is the data analytics platform\u2019s deep dive into the headline numbers for 2017. While the … Continue reading "Pharma companies prominent in list of top defendants in US patent litigation during 2017"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dominiclevent.com\/blog\/pharma-companies-prominent-in-list-of-top-defendants-in-us-patent-litigation-during-2017\/\" \/>\n<meta property=\"og:site_name\" content=\"Dominic Levent Solicitors Blog\" \/>\n<meta property=\"article:published_time\" content=\"2018-02-12T09:28:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-04-17T17:14:53+00:00\" \/>\n<meta name=\"author\" content=\"spainops\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"spainops\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dominiclevent.com\/blog\/pharma-companies-prominent-in-list-of-top-defendants-in-us-patent-litigation-during-2017\/\",\"url\":\"https:\/\/dominiclevent.com\/blog\/pharma-companies-prominent-in-list-of-top-defendants-in-us-patent-litigation-during-2017\/\",\"name\":\"Pharma companies prominent in list of top defendants in US patent litigation during 2017 - Dominic Levent Solicitors Blog\",\"isPartOf\":{\"@id\":\"https:\/\/dominiclevent.com\/blog\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dominiclevent.com\/blog\/pharma-companies-prominent-in-list-of-top-defendants-in-us-patent-litigation-during-2017\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dominiclevent.com\/blog\/pharma-companies-prominent-in-list-of-top-defendants-in-us-patent-litigation-during-2017\/#primaryimage\"},\"thumbnailUrl\":\"http:\/\/dominiclevent.com\/blog\/wp-content\/uploads\/2017\/11\/litigation-300x225.jpg\",\"datePublished\":\"2018-02-12T09:28:56+00:00\",\"dateModified\":\"2019-04-17T17:14:53+00:00\",\"author\":{\"@id\":\"https:\/\/dominiclevent.com\/blog\/#\/schema\/person\/bacc79b48921539cd8fc642f86d23254\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dominiclevent.com\/blog\/pharma-companies-prominent-in-list-of-top-defendants-in-us-patent-litigation-during-2017\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dominiclevent.com\/blog\/pharma-companies-prominent-in-list-of-top-defendants-in-us-patent-litigation-during-2017\/#primaryimage\",\"url\":\"http:\/\/dominiclevent.com\/blog\/wp-content\/uploads\/2017\/11\/litigation-300x225.jpg\",\"contentUrl\":\"http:\/\/dominiclevent.com\/blog\/wp-content\/uploads\/2017\/11\/litigation-300x225.jpg\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dominiclevent.com\/blog\/#website\",\"url\":\"https:\/\/dominiclevent.com\/blog\/\",\"name\":\"Dominic Levent Solicitors Blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dominiclevent.com\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/dominiclevent.com\/blog\/#\/schema\/person\/bacc79b48921539cd8fc642f86d23254\",\"name\":\"spainops\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dominiclevent.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/6a2648c0ace71d8dde31f2a9e8b370b694f81d70a3ed9ccfb9ec45550a223943?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/6a2648c0ace71d8dde31f2a9e8b370b694f81d70a3ed9ccfb9ec45550a223943?s=96&d=mm&r=g\",\"caption\":\"spainops\"},\"sameAs\":[\"https:\/\/dominiclevent.com\/blog\"],\"url\":\"https:\/\/dominiclevent.com\/blog\/author\/spainops\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharma companies prominent in list of top defendants in US patent litigation during 2017 - Dominic Levent Solicitors Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dominiclevent.com\/blog\/pharma-companies-prominent-in-list-of-top-defendants-in-us-patent-litigation-during-2017\/","og_locale":"en_US","og_type":"article","og_title":"Pharma companies prominent in list of top defendants in US patent litigation during 2017 - Dominic Levent Solicitors Blog","og_description":"Teva was the most targeted company in US patent lawsuits last year taking the top spot from Samsung as pharmaceutical companies featured heavily in the leading defendants. The numbers come courtesy of Lex Machina\u2019s annual review of patent litigation, which is the data analytics platform\u2019s deep dive into the headline numbers for 2017. While the … Continue reading \"Pharma companies prominent in list of top defendants in US patent litigation during 2017\"","og_url":"https:\/\/dominiclevent.com\/blog\/pharma-companies-prominent-in-list-of-top-defendants-in-us-patent-litigation-during-2017\/","og_site_name":"Dominic Levent Solicitors Blog","article_published_time":"2018-02-12T09:28:56+00:00","article_modified_time":"2019-04-17T17:14:53+00:00","author":"spainops","twitter_card":"summary_large_image","twitter_misc":{"Written by":"spainops","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dominiclevent.com\/blog\/pharma-companies-prominent-in-list-of-top-defendants-in-us-patent-litigation-during-2017\/","url":"https:\/\/dominiclevent.com\/blog\/pharma-companies-prominent-in-list-of-top-defendants-in-us-patent-litigation-during-2017\/","name":"Pharma companies prominent in list of top defendants in US patent litigation during 2017 - Dominic Levent Solicitors Blog","isPartOf":{"@id":"https:\/\/dominiclevent.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dominiclevent.com\/blog\/pharma-companies-prominent-in-list-of-top-defendants-in-us-patent-litigation-during-2017\/#primaryimage"},"image":{"@id":"https:\/\/dominiclevent.com\/blog\/pharma-companies-prominent-in-list-of-top-defendants-in-us-patent-litigation-during-2017\/#primaryimage"},"thumbnailUrl":"http:\/\/dominiclevent.com\/blog\/wp-content\/uploads\/2017\/11\/litigation-300x225.jpg","datePublished":"2018-02-12T09:28:56+00:00","dateModified":"2019-04-17T17:14:53+00:00","author":{"@id":"https:\/\/dominiclevent.com\/blog\/#\/schema\/person\/bacc79b48921539cd8fc642f86d23254"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dominiclevent.com\/blog\/pharma-companies-prominent-in-list-of-top-defendants-in-us-patent-litigation-during-2017\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dominiclevent.com\/blog\/pharma-companies-prominent-in-list-of-top-defendants-in-us-patent-litigation-during-2017\/#primaryimage","url":"http:\/\/dominiclevent.com\/blog\/wp-content\/uploads\/2017\/11\/litigation-300x225.jpg","contentUrl":"http:\/\/dominiclevent.com\/blog\/wp-content\/uploads\/2017\/11\/litigation-300x225.jpg"},{"@type":"WebSite","@id":"https:\/\/dominiclevent.com\/blog\/#website","url":"https:\/\/dominiclevent.com\/blog\/","name":"Dominic Levent Solicitors Blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dominiclevent.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/dominiclevent.com\/blog\/#\/schema\/person\/bacc79b48921539cd8fc642f86d23254","name":"spainops","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dominiclevent.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/6a2648c0ace71d8dde31f2a9e8b370b694f81d70a3ed9ccfb9ec45550a223943?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6a2648c0ace71d8dde31f2a9e8b370b694f81d70a3ed9ccfb9ec45550a223943?s=96&d=mm&r=g","caption":"spainops"},"sameAs":["https:\/\/dominiclevent.com\/blog"],"url":"https:\/\/dominiclevent.com\/blog\/author\/spainops\/"}]}},"_links":{"self":[{"href":"https:\/\/dominiclevent.com\/blog\/wp-json\/wp\/v2\/posts\/28034","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dominiclevent.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dominiclevent.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dominiclevent.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dominiclevent.com\/blog\/wp-json\/wp\/v2\/comments?post=28034"}],"version-history":[{"count":0,"href":"https:\/\/dominiclevent.com\/blog\/wp-json\/wp\/v2\/posts\/28034\/revisions"}],"wp:attachment":[{"href":"https:\/\/dominiclevent.com\/blog\/wp-json\/wp\/v2\/media?parent=28034"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dominiclevent.com\/blog\/wp-json\/wp\/v2\/categories?post=28034"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dominiclevent.com\/blog\/wp-json\/wp\/v2\/tags?post=28034"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}